Author

N. Sindoni

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:metabolism & bioenergetics· 1 Assay:proteomics· 1

Frequent Co-Authors

J. D. Mancias· 2 shared A. D. Patterson· 1 shared A. J. Aguirre· 1 shared A. Padhye· 1 shared A. Parolia· 1 shared B. Chen· 1 shared B. S. Halligan· 1 shared C. A. Lyssiotis· 1 shared

Activity by Year

2024-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. D. Mancias

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer

H. Zhang, Q. Yu, N. Santana-Codina, C. Poupault, C. Campos, X. Qin, A. Padhye, N. Sindoni, M. Kuljanin, J. Wang, M. J. Dorman, A. J. Aguirre, S. K. Dougan, K. A. Sarosiek, J. D. Mancias

This study identifies that combining DHODH inhibition with BCL-XL targeting synergistically induces apoptosis in pancreatic cancer, offering a new combination therapy strategy.

bioRxiv · May 17, 2024 · PreprintCancer Biology

BRD4-mediated epigenetic regulation of endoplasmic reticulum-mitochondria contact sites is governed by the mitochondrial complex III

B. Chen, D. C. Stark, P. V. Jadhav, T. M. Lynn-Nguyen, B. S. Halligan, N. J. Rossiter, N. Sindoni, M. Shin, J. A. Paulo, M. Chang, I. Koo, S. Koshkin, S. Eyunni, P. Ronchi, M. T. Paulsen, , Y. M. Shah

The paper identifies fedratinib as a drug that increases endoplasmic reticulum-mitochondria contact sites by inhibiting BRD4, revealing a novel epigenetic pathway linking ERMCS to cellular metabolism.

bioRxiv · Feb 2, 2024 · PreprintCell Biology